Erythropoietin: a future therapy for failing hearts?

Lindsey Tilling*, Brian Clapp

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    4 Citations (Scopus)

    Abstract

    Recently, it has been suggested that erythropoietin may be useful in the treatment of cardiovascular disease, particularly heart failure. This may be by improving microvascular blood supply and ventricular function through prevention of apoptosis and angiogenesis. Promising results were seen in animals but the few, limited clinical trials have shown modest benefits. Additionally, concerns exist regarding potential serious adverse effects of erythropoietin. Our current understanding of the non-haematopoietic mechanisms of erythropoietin is presented here, with a review of trials to date, and a discussion of the questions that remain over the use of this drug in heart failure.

    Original languageEnglish
    Pages (from-to)475-483
    Number of pages9
    JournalHeart Failure Reviews
    Volume17
    Issue number3
    DOIs
    Publication statusPublished - May 2012

    Keywords

    • Erythropoietin
    • Heart failure
    • Ischaemia
    • Signalling
    • ACUTE MYOCARDIAL-INFARCTION
    • CHRONIC KIDNEY-DISEASE
    • NITRIC-OXIDE SYNTHASE
    • ISCHEMIA-REPERFUSION INJURY
    • IMPROVES CARDIAC-FUNCTION
    • DARBEPOETIN-ALPHA
    • INTRAVENOUS IRON
    • FAILURE PATIENTS
    • PROGENITOR CELLS
    • DOUBLE-BLIND

    Fingerprint

    Dive into the research topics of 'Erythropoietin: a future therapy for failing hearts?'. Together they form a unique fingerprint.

    Cite this